Technology Bundle ID
TAB-2339

AAV Mediated CTLA-4 Gene Transfer to Treat Sjogren's Syndrome

Applications
Therapeutics
Linked ID
E-087-2011-0
Lead Inventors
Hongen Yin (NIDCR)
Co-Inventors
John Chiorini (NIDCR)
Development Status
  • In vitro data available
  • In vivo data available (animal)
Therapeutic Areas
Immunology
ICs
NIDCR
Sjögren’s syndrome is an autoimmune disease that affects over 2 million Americans, primarily over the age of 40. One of the major outcomes of Sjögren's syndrome is xerostomia (dry mouth) that is caused by immune system attack on moisture producing salivary glands. Researchers at the National Institute of Dental and Craniofacial Research have developed a therapy that alleviates xerostomia in a murine model of Sjögren's syndrome. This technology consists of a local delivery of adeno-associated virus (AAV) mediated cytotoxic T-lymphocyte antigen 4 Immunoglobulin-G (CTLA4IgG) fusion protein to salivary glands. The system effectively blocks CTLA4 ligand interactions with T cell surface receptors, resulting in immune suppression and reversal of autoimmune-related xerostomia. Targeted delivery of the AAV-CTLA4-IgG system makes this invention a novel therapeutic for the prevention of xerostomia-associated pain and discomfort caused by Sjögren's syndrome.
Commercial Applications
Prevention of salivary gland destruction and xerostomia development in patients with Sjögren's syndrome.
Competitive Advantages
  • Current treatments temporarily reduce the discomfort of xerostomia but do not prevent the deleterious effects of this disorder.
  • AAV gene transfer to salivary glands is highly efficient.
  • AAV therapy is safe and noninflammatory.

Request More Info

Licensing Contact: